Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ELUT
Upturn stock ratingUpturn stock rating

Elutia Inc. (ELUT)

Upturn stock ratingUpturn stock rating
$1.98
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: ELUT (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

2 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $7.5

1 Year Target Price $7.5

Analysts Price Target For last 52 week
$7.5Target price
Low$1.61
Current$1.98
high$5.15

Analysis of Past Performance

Type Stock
Historic Profit -28.1%
Avg. Invested days 22
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 86.34M USD
Price to earnings Ratio -
1Y Target Price 7.5
Price to earnings Ratio -
1Y Target Price 7.5
Volume (30-day avg) 2
Beta 0.86
52 Weeks Range 1.61 - 5.15
Updated Date 06/30/2025
52 Weeks Range 1.61 - 5.15
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.32

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -168.23%
Operating Margin (TTM) -88.72%

Management Effectiveness

Return on Assets (TTM) -38.41%
Return on Equity (TTM) -

Valuation

Trailing PE -
Forward PE -
Enterprise Value 93589737
Price to Sales(TTM) 3.64
Enterprise Value 93589737
Price to Sales(TTM) 3.64
Enterprise Value to Revenue 3.95
Enterprise Value to EBITDA -3.32
Shares Outstanding 36802300
Shares Floating 14266724
Shares Outstanding 36802300
Shares Floating 14266724
Percent Insiders 6.17
Percent Institutions 72.65

Analyst Ratings

Rating 2
Target Price 7.5
Buy -
Strong Buy 2
Buy -
Strong Buy 2
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Elutia Inc.

stock logo

Company Overview

overview logo History and Background

Elutia, Inc., formerly known as Conformis, Inc., was founded in 2004. It initially focused on patient-specific orthopedic implants. Over time, it transitioned to regenerative biomaterials and resorbable polymer solutions. The company rebranded as Elutia in 2023 to reflect its broader focus.

business area logo Core Business Areas

  • Regenerative Biomaterials: Elutia develops and markets a range of regenerative biomaterials used in surgical procedures, including soft tissue repair, wound management, and bone regeneration. These products leverage resorbable polymer technology.
  • Resorbable Polymers: Elutia offers resorbable polymer solutions for medical device applications. They design and manufacture customized polymer materials for use in implants and other medical products.

leadership logo Leadership and Structure

As of January 2024, the CEO is Terrence D. Brown. The organizational structure includes departments for research and development, manufacturing, sales and marketing, and finance and operations.

Top Products and Market Share

overview logo Key Offerings

  • Canalux: Canalux is a resorbable sinus spacer used in sinus surgery. Market share data is not readily available. Competitors include Stryker (SYK), Medtronic (MDT), and Johnson & Johnson (JNJ).
  • SurgiBind: SurgiBind is a resorbable soft tissue scaffold used in surgical procedures to reinforce and repair soft tissues. Market share data is not readily available. Competitors include Aziyo Biologics, MTF Biologics and numerous small private companies.

Market Dynamics

industry overview logo Industry Overview

The regenerative medicine and biomaterials market is experiencing significant growth, driven by aging populations, increasing demand for minimally invasive procedures, and technological advancements in tissue engineering and biomaterial science.

Positioning

Elutia is positioned as a player in the regenerative medicine and biomaterials market, focusing on resorbable polymer technologies. Their competitive advantages include their proprietary polymer formulations and focus on specific surgical applications.

Total Addressable Market (TAM)

The total addressable market for regenerative biomaterials is estimated to be in the billions of dollars. Elutia's positioning targets specific sub-segments like sinus surgery and soft tissue repair.

Upturn SWOT Analysis

Strengths

  • Proprietary resorbable polymer technology
  • Focus on specific surgical applications
  • Experienced management team
  • Established distribution network

Weaknesses

  • Limited market share compared to larger competitors
  • Dependence on key products
  • Relatively small size and resources
  • Profitability not consistently demonstrated

Opportunities

  • Expanding product portfolio into new surgical areas
  • Strategic partnerships and acquisitions
  • Increasing adoption of minimally invasive procedures
  • Growth in emerging markets

Threats

  • Intense competition from larger companies
  • Regulatory hurdles and product approval timelines
  • Pricing pressures from healthcare providers
  • Potential for product liability claims

Competitors and Market Share

competitor logo Key Competitors

  • Stryker (SYK)
  • Medtronic (MDT)
  • Johnson & Johnson (JNJ)
  • Aziyo Biologics (AZYO)

Competitive Landscape

Elutia faces intense competition from larger, more established medical device companies. Elutia's advantage lies in its specialized focus on resorbable polymer technologies, but it needs to expand market presence.

Major Acquisitions

None

  • Year: 0
  • Acquisition Price (USD millions): 0
  • Strategic Rationale: No acquisitions to report.

Growth Trajectory and Initiatives

Historical Growth: Elutia has experienced fluctuations in revenue growth due to the transition from orthopedic implants to regenerative biomaterials. Historical growth figures are impacted by discontinued product lines.

Future Projections: Analyst estimates for future growth are dependent on the successful commercialization of new products and expansion into new markets. Projections vary.

Recent Initiatives: Recent strategic initiatives include rebranding the company as Elutia, focusing on regenerative biomaterials, and expanding the sales and marketing team.

Summary

Elutia Inc. is a regenerative biomaterials company undergoing a strategic shift. While they possess proprietary technology and a focused approach, they face competition from larger players. Successful commercialization of new products and market expansion are crucial for future growth. The company's financial performance and shareholder returns have been volatile in the recent past as the company transitioned to its new strategy.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Analyst Reports (Estimates)
  • Market Research Reports

Disclaimers:

This analysis is based on available information and estimates. Market conditions and company performance are subject to change. This is not financial advice.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Elutia Inc.

Exchange NASDAQ
Headquaters Silver Spring, MD, United States
IPO Launch date 2023-09-07
Co-Founder, President, CEO & Director Dr. C. Randal Mills Ph.D.
Sector Healthcare
Industry Medical Devices
Full time employees 51
Full time employees 51

Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation and breast reconstruction in the United States. It operates in three segments: Device Protection, Women's Health, and Cardiovascular. The company offers EluPro, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators; and CanGaroo, which mitigates complications derived from implantable electronic devices and shortcomings of synthetic envelopes. It also provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material used to repair or reconstruct the peripheral vasculature. In addition, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction. It serves hospitals and healthcare facilities through its direct sales force, commercial partners, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.